{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:25:27Z","timestamp":1761963927077,"version":"3.30.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,7,2]],"date-time":"2001-07-02T00:00:00Z","timestamp":994032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sixty\u2010two adults underwent marrow or blood stem cell transplantation from an HLA\u2010matched related donor using high\u2010dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission. All evaluable patients engrafted and had complete donor chimerism. A grade 3\u20134 regimen\u2010related toxicity occurred in eight (13%) patients, and a diagnosis of MDS was the only independent risk factor for grade 3\u20134 regimen\u2010related toxicity (hazard ratio 9.25,<jats:italic>P<\/jats:italic>= 0.01). Day\u2010100 treatment\u2010related mortality (TRM) was 19%. Poor\u2010prognosis cytogenetics increased the risk of day\u2010100 TRM (hazard ratio 11.4,<jats:italic>P<\/jats:italic>= 0.003), and use of tacrolimus for graft\u2010versus\u2010host disease prophylaxis reduced the risk of day\u2010100 TRM (hazard ratio 0.13,<jats:italic>P<\/jats:italic>= 0.027). For all patients, the three\u2010year relapse rate was 43% (95% CI, 28%\u201358%). Refractoriness to conventional induction chemotherapy prior to transplantation was an independent risk factor for relapse (hazard ratio 10.8,<jats:italic>P<\/jats:italic>= 0.02). Three\u2010year survival was 26% (95% CI, 14%\u201337%); survival rates were 29% for those transplanted for AML in second remission, 31% transplanted for AML in relapse, and 17% with MDS, and there were no independent risk factors for survival. TBC is an active preparative regimen for advanced AML. Patients with advanced MDS appeared to have a higher risk of toxicity and early mortality, and alternative preparative regimens should be considered for these patients. Am. J. Hematol. 67:227\u2013233, 2001. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.1121","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T21:59:21Z","timestamp":1030312761000},"page":"227-233","source":"Crossref","is-referenced-by-count":22,"title":["Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia"],"prefix":"10.1002","volume":"67","author":[{"given":"Samer","family":"Bibawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Abi\u2010Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,7,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_1_3_2","first-page":"21","article-title":"High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB\u2010t) given acute myelogenous leukemia (AML)\u2010type chemotherapy in combination with granulocyte\u2010CSF (G\u2010CSF)","volume":"1","author":"Estey EH","year":"1995","journal-title":"Cytokines Mol Ther"},{"key":"e_1_2_1_4_2","first-page":"1443","article-title":"Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first\u2010line induction therapy: a GIMEMA study of 218 unselected consecutive patients","author":"Liso V","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050163"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401568"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/blood.V93.9.3149","article-title":"Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy","volume":"93","author":"Vey N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900901)66:5<831::AID-CNCR2820660503>3.0.CO;2-E"},{"key":"e_1_2_1_9_2","first-page":"13","article-title":"Chemotherapy versus transplants for acute myelogenous leukemia in second remission","volume":"10","author":"Gale RP","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.51.51"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","article-title":"A prospective randomized comparison of total body irradiation\u2013etoposide versus busulfa\u2010cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study","volume":"81","author":"Blume KG","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1200\/JCO.1994.12.9.1923","article-title":"Etoposide, cyclophosphamide, total\u2010body irradiation and allogeneic bone marrow transplantation for hematologic malignancies","volume":"12","author":"Giralt SA","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.V85.5.1391.bloodjournal8551391","article-title":"High\u2010dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Transplant Group","volume":"85","author":"Brown RA","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051758"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.963"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.220"},{"key":"e_1_2_1_17_2","first-page":"489","article-title":"Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy","volume":"8","author":"Vaughan WP","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"e_1_2_1_18_2","first-page":"2","article-title":"High\u2010dose N,N\u2032,N\u2032\u2032\u2010triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies","volume":"17","author":"Wolff SN","year":"1990","journal-title":"Sem Oncol"},{"key":"e_1_2_1_19_2","first-page":"449","article-title":"A Phase I\u2013II study of high\u2010dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation","volume":"14","author":"Przepiorka D","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199612270-00022"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(87)90017-8"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_1_23_2","first-page":"825","article-title":"Report of the 1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.1922.0009"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_1_26_2","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-8-590"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(92)90019-M"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2973"},{"key":"e_1_2_1_31_2","first-page":"203","article-title":"Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission","volume":"16","author":"Gale RP","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_32_2","first-page":"993","article-title":"Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC\u2010GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups","volume":"17","author":"Keating S","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_33_2","first-page":"2931","article-title":"Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study","volume":"90","author":"Ferrant A","year":"1997","journal-title":"Blood"},{"issue":"2","key":"e_1_2_1_34_2","first-page":"40","article-title":"Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia","volume":"7","author":"De Witte T","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","article-title":"Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation","volume":"92","author":"Nevill TJ","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02558.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.677.677"},{"key":"e_1_2_1_38_2","first-page":"745","article-title":"Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA\u2010identical sibling and alternative donors","volume":"17","author":"Demuynck H","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_39_2","first-page":"1085","article-title":"Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia","volume":"84","author":"Witherspoon RP","year":"1999","journal-title":"Haematol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.7.407"},{"key":"e_1_2_1_41_2","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone G","year":"1999","journal-title":"Haematol"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1558"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.1987.5.5.731","article-title":"Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease","volume":"5","author":"Sargur M","year":"1987","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1707"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.4.1090.1090"},{"key":"e_1_2_1_46_2","first-page":"415","article-title":"Bone marrow transplantation for primary refractory acute leukaemia","volume":"14","author":"Mehta J","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702051"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.1121","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.1121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:36:55Z","timestamp":1733157415000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.1121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,2]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1002\/ajh.1121"],"URL":"https:\/\/doi.org\/10.1002\/ajh.1121","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"type":"print","value":"0361-8609"},{"type":"electronic","value":"1096-8652"}],"subject":[],"published":{"date-parts":[[2001,7,2]]}}}